 |
|
Treatment of Tardive DyskinesiaI. Clinical Efficacy of a Dopamine-Depleting Agent, Tetrabenazine
Hajime Kazamatsuri, MD;
Ching-piao Chien, MD;
Jonathan O. Cole, MD
Arch Gen Psychiatry. 1972;27(1):95-99.
Abstract
Tardive dyskinesia is becoming detectable in increasing numbers of chronic psychiatric patients. More than 24 such patients were identified among approximately 400 ambulatory long-term patients at Boston State Hospital. This study demonstrates that tetrabenazine (Nitoman [Great Britain]), a dopamine-depleting agent, significantly reduces the frequency of abnormal mouth, jaw, and tongue movements at dosages up to 150 mg/day. The intensity of these movements and of associated abnormal movements of the extremities and trunk were also reduced. Reversible extrapyramidal symptoms were not increased at the dosage used. The antidyskinetic effect was marked in two thirds of the patients. The results of the study are consistent with the hypothesis that the abnormal movements of tardive dyskinesia might result from overactivity of dopaminergic neurones in the basal ganglia.
Author Affiliations
Boston
From Boston State Hospital (Drs. Kazamatsuri, Chien, and Cole) and Tufts University School of Medicine (Drs. Chien and Cole). Dr. Kazamatsuri was on leave from Tokyo University School of Medicine at the time this paper was written. He is currently a professor of Teikyo University School of Medicine, Tokyo.
Footnotes
Accepted for publication Oct 18, 1971.
Reprint requests to 6-1-6, Shimorenjaku, Mitaka, Tokyo, 181, Japan (Dr. Kazamatsuri).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Efficacy of the Branched-Chain Amino Acids in the Treatment of Tardive Dyskinesia in Men
Richardson et al.
Am. J. Psychiatry 2003;160:1117-1124.
ABSTRACT
| FULL TEXT
Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol
Ondo et al.
Am. J. Psychiatry 1999;156:1279-1281.
ABSTRACT
| FULL TEXT
Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience
Jeste and Jed Wyatt
Arch Gen Psychiatry 1982;39:803-816.
ABSTRACT
The Assessment of Tardive Dyskinesia
Gardos et al.
Arch Gen Psychiatry 1977;34:1206-1212.
ABSTRACT
Spontaneous Oral Dyskinesia: Results of Treatment With Tetrabenazine, Pimozide, or Both
Pakkenberg and Fog
Arch Neurol 1974;31:352-353.
ABSTRACT
Neurological Syndromes Associated With Antipsychotic Drug Use: A Special Report
FREEDMAN
Arch Gen Psychiatry 1973;28:463-467.
ABSTRACT
Treatment of Tardive Dyskinesia: III. Clinical Efficacy of a Dopamine Competing Agent, Methyldopa
Kazamatsuri et al.
Arch Gen Psychiatry 1972;27:824-827.
ABSTRACT
Therapeutic Approaches to Tardive Dyskinesia: A Review of the Literature
Kazamatsuri et al.
Arch Gen Psychiatry 1972;27:491-499.
ABSTRACT
Treatment of Tardive Dyskinesia: II. Short-Term Efficacy of Dopamine-Blocking Agents Haloperidol and Thiopropazate
Kazamatsuri et al.
Arch Gen Psychiatry 1972;27:100-103.
ABSTRACT
|
